Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 590851, 8 pages
http://dx.doi.org/10.1155/2015/590851
Clinical Study

Inflammatory Biomarkers in Refractory Congestive Heart Failure Patients Treated with Peritoneal Dialysis

1Nephrology and Hypertension Institute, Sheba Medical Center and Sackler Faculty of Medicine, 5265601 Tel-Hashomer, Israel
2Heart Failure Service and Heart Institute, Sheba Medical Center and Sackler Faculty of Medicine, 5265601 Tel-Hashomer, Israel

Received 4 March 2015; Revised 4 May 2015; Accepted 5 May 2015

Academic Editor: Francesco Nicolini

Copyright © 2015 Margarita Kunin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Nakayama, “Nonuremic indication for peritoneal dialysis for refractory heart failure in cardiorenal syndrome type II: review and perspective,” Peritoneal Dialysis International, vol. 33, no. 1, pp. 8–14, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. E. A. Ross and A. Kazory, “Ultrafiltration therapy for cardiorenal syndrome: physiologic basis and contemporary options,” Blood Purification, vol. 34, no. 2, pp. 149–157, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. T. T. Cnossen, J. P. Kooman, C. J. A. M. Konings, N. H. M. K. Uszko-Lencer, K. M. L. Leunissen, and F. M. van der Sande, “Peritoneal dialysis in patients with primary cardiac failure complicated by renal failure,” Blood Purification, vol. 30, no. 2, pp. 146–152, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. J. E. Sánchez, T. Ortega, C. Rodríguez et al., “Efficacy of peritoneal ultrafiltration in the treatment of refractory congestive heart failure,” Nephrology Dialysis Transplantation, vol. 25, no. 2, pp. 605–610, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. N. G. Sotirakopoulos, I. M. Kalogiannidou, M. E. Tersi, and K. S. Mavromatidis, “Peritoneal dialysis for patients suffering from severe heart failure,” Clinical Nephrology, vol. 76, no. 2, pp. 124–129, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Kunin, M. Arad, D. Dinour, D. Freimark, and E. J. Holtzman, “Peritoneal dialysis in patients with refractory congestive heart failure: potential prognostic factors,” Blood Purification, vol. 35, no. 4, pp. 285–294, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Levine, J. Kalman, L. Mayer, H. M. Fillit, and M. Packer, “Elevated circulating levels of tumor necrosis factor in severe chronic heart failure,” The New England Journal of Medicine, vol. 323, no. 4, pp. 236–241, 1990. View at Publisher · View at Google Scholar · View at Scopus
  8. D. L. Mann, “Inflammatory mediators and the failing heart: past, present, and the foreseeable future,” Circulation Research, vol. 91, no. 11, pp. 988–998, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Bozkurt, D. L. Mann, and A. Deswal, “Biomarkers of inflammation in heart failure,” Heart Failure Reviews, vol. 15, no. 4, pp. 331–341, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Torre-Amione, S. Kapadia, J. Lee et al., “Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart,” Circulation, vol. 93, no. 4, pp. 704–711, 1996. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Kapadia, J. R. Lee, G. Torre-Amione, H. H. Birdsall, T. S. Ma, and D. L. Mann, “Tumor necrosis factor-α gene and protein expression in adult feline myocardium after endotoxin administration,” The Journal of Clinical Investigation, vol. 96, no. 2, pp. 1042–1052, 1995. View at Publisher · View at Google Scholar · View at Scopus
  12. D. L. Mann and J. B. Young, “Basic mechanisms in congestive heart failure: recognizing the role of proinflammatory cytokines,” Chest, vol. 105, no. 3, pp. 897–904, 1994. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Matsumori, T. Yamada, H. Suzuki, Y. Matoba, and S. Sasayama, “Increased circulating cytokines in patients with myocarditis and cardiomyopathy,” British Heart Journal, vol. 72, no. 6, pp. 561–566, 1994. View at Publisher · View at Google Scholar · View at Scopus
  14. T. S. Gulick, M. K. Chung, S. J. Pieper, L. G. Lange, and G. F. Schreiner, “Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 17, pp. 6753–6757, 1989. View at Publisher · View at Google Scholar · View at Scopus
  15. K. A. Krown, M. T. Page, C. Nguyen et al., “Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death,” Journal of Clinical Investigation, vol. 98, no. 12, pp. 2854–2865, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. M. O. Boluyt, L. O'Neill, A. L. Meredith et al., “Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure: marked upregulation of genes encoding extracellular matrix components,” Circulation Research, vol. 75, no. 1, pp. 23–32, 1994. View at Publisher · View at Google Scholar · View at Scopus
  17. K. W. Moore, A. O'Garra, R. de Waal Malefyt, P. Vieira, and T. R. Mosmann, “Interleukin-10,” Annual Review of Immunology, vol. 11, pp. 165–190, 1993. View at Publisher · View at Google Scholar · View at Scopus
  18. S. M. Wahl, “Transforming growth factor beta (TGF-β) in inflammation: a cause and a cure,” Journal of Clinical Immunology, vol. 12, no. 2, pp. 61–74, 1992. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Ronco, C. Tetta, A. Lupi et al., “Removal of platelet-activating factor in experimental continuous arteriovenous hemofiltration,” Critical Care Medicine, vol. 23, no. 1, pp. 99–107, 1995. View at Publisher · View at Google Scholar · View at Scopus
  20. J. A. Kellum, J. P. Johnson, D. Kramer, P. Palevsky, J. J. Brady, and M. R. Pinsky, “Diffusive versus convective therapy: effects on mediators of inflammation in patients with severe systemic inflammatory in patients with severe systemic inflammatory response syndrome,” Critical Care Medicine, vol. 26, pp. 1995–2000, 1998. View at Google Scholar
  21. A. S. de Vriese, F. A. Colardyn, J. J. Philippé, R. C. Vanholder, J. H. de Sutter, and N. H. Lameire, “Cytokine removal during continuous hemofiltration in septic patients,” Journal of the American Society of Nephrology, vol. 10, no. 4, pp. 846–853, 1999. View at Google Scholar · View at Scopus
  22. C. Libetta, V. Sepe, M. Zucchi et al., “Intermittent haemodiafiltration in refractory congestive heart failure: BNP and balance of inflammatory cytokines,” Nephrology Dialysis Transplantation, vol. 22, no. 7, pp. 2013–2019, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Pecoits-Filho, P. Stenvinkel, A. Yee-Moon Wang, O. Heimbürger, and B. Lindholm, “Chronic inflammation in peritoneal dialysis: the search for the holy grail?” Peritoneal Dialysis International, vol. 24, no. 4, pp. 327–339, 2004. View at Google Scholar · View at Scopus
  24. A. Worster, C. M. Balion, S. A. Hill et al., “Diagnostic accuracy of BNP and NT-proBNP in patients presenting to acute care settings with dyspnea: a systematic review,” Clinical Biochemistry, vol. 41, no. 4-5, pp. 250–259, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Harrison, L. K. Morrison, P. Krishnaswamy et al., “B-Type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea,” Annals of Emergency Medicine, vol. 39, no. 2, pp. 131–138, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Valle, N. Aspromonte, E. Carbonieri et al., “Fall in readmission rate for heart failure after implementation of B-type natriuretic peptide testing for discharge decision: a retrospective study,” International Journal of Cardiology, vol. 126, no. 3, pp. 400–406, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. J. L. Januzzi Jr. and R. Troughton, “Serial natriuretic peptide measurements are useful in heart failure management,” Circulation, vol. 127, no. 4, pp. 500–508, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. R. P. Tracy, “Inflammation markers and coronary heart disease,” Current Opinion in Lipidology, vol. 10, no. 5, pp. 435–441, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Pye, A. P. Rae, and S. M. Cobbe, “Study of serum C-reactive protein concentration in cardiac failure,” British Heart Journal, vol. 63, no. 4, pp. 228–230, 1990. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Kaneko, T. Kanda, Y. Yamauchi et al., “C-Reactive protein in dilated cardiomyopathy,” Cardiology, vol. 91, no. 4, pp. 215–219, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. O. Milo, G. Cotter, E. Kaluski et al., “Comparison of inflammatory and neurohormonal activation in cardiogenic pulmonary edema secondary to ischemic versus nonischemic causes,” American Journal of Cardiology, vol. 92, no. 2, pp. 222–226, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. J. L. Alonso-Martínez, B. Llorente-Diez, M. Echegaray-Agara, F. Olaz-Preciado, M. Urbieta-Echezarreta, and C. González-Arencibia, “C-reactive protein as a predictor of improvement and readmission in heart failure,” European Journal of Heart Failure, vol. 4, no. 3, pp. 331–336, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Cesari, B. W. J. H. Penninx, A. B. Newman et al., “Inflammatory markers and onset of cardiovascular events: results from the Health ABC study,” Circulation, vol. 108, no. 19, pp. 2317–2322, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. R. S. Vasan, L. M. Sullivan, R. Roubenoff et al., “Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study,” Circulation, vol. 107, no. 11, pp. 1486–1491, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. K. E. Joynt, W. A. Gattis, V. Hasselblad et al., “Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure,” The American Journal of Cardiology, vol. 93, no. 6, pp. 783–785, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. D. P. Dutka, J. S. Elborn, F. Delamere, D. J. Shale, and G. K. Morris, “Tumour necrosis factor alpha in severe congestive cardiac failure,” British Heart Journal, vol. 70, no. 2, pp. 141–143, 1993. View at Publisher · View at Google Scholar · View at Scopus
  37. S. M. Dunlay, S. A. Weston, M. M. Redfield, J. M. Killian, and V. L. Roger, “Tumor necrosis factor-α and mortality in heart failure: a community study,” Circulation, vol. 118, no. 6, pp. 625–631, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Gurlek, M. Kilickap, I. Dincer, R. Dandachi, H. Tutkak, and D. Oral, “Effect of losartan on circulating TNFα levels and left ventricular systolic performance in patients with heart failure,” Journal of Cardiovascular Risk, vol. 8, no. 5, pp. 279–282, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Loppnow, K. Werdan, and C. Werner, “The enhanced plasma levels of soluble tumor necrosis factor receptors (sTNF-R1; sTNF-R2) and interleukin-10 (IL-10) in patients suffering from chronic heart failure are reversed in patients treated with β-adrenoceptor antagonist,” Autonomic and Autacoid Pharmacology, vol. 22, no. 2, pp. 83–92, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Aronson and A. J. Burger, “Effect of beta-blockade on autonomic modulation of heart rate and neurohormonal profile in decompensated heart failure,” Annals of Noninvasive Electrocardiology, vol. 6, no. 2, pp. 98–106, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. J. R. Gage, G. Fonarow, M. Hamilton, M. Widawski, O. Martínez-Maza, and D. L. Vredevoe, “Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure,” NeuroImmunoModulation, vol. 11, no. 3, pp. 173–180, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Matsumura, K. Tsushima, E. Ohtaki et al., “Effects of carvedilol on plasma levels of interleukin-6 and tumor necrosis factor-alpha in nine patients with dilated cardiomyopathy,” Journal of Cardiology, vol. 39, no. 5, pp. 253–257, 2002. View at Google Scholar · View at Scopus
  43. T. Ohtsuka, M. Hamada, G. Hiasa et al., “Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy,” Journal of the American College of Cardiology, vol. 37, no. 2, pp. 412–417, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Tsutamoto, A. Wada, T. Matsumoto et al., “Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy,” Journal of the American College of Cardiology, vol. 37, no. 8, pp. 2086–2092, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. E. R. Mohler III, L. C. Sorensen, J. K. Ghali et al., “Role of cytokines in the mechanism of action of amlodipine: the PRAISE heart failure trial,” Journal of the American College of Cardiology, vol. 30, no. 1, pp. 35–41, 1997. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Maeda, T. Tsutamoto, A. Wada et al., “High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure,” Journal of the American College of Cardiology, vol. 36, no. 5, pp. 1587–1593, 2000. View at Publisher · View at Google Scholar · View at Scopus
  47. P. Aukrust, T. Ueland, F. Müller et al., “Elevated circulating levels of C–C chemokines in patients with congestive heart failure,” Circulation, vol. 97, no. 12, pp. 1136–1143, 1998. View at Publisher · View at Google Scholar · View at Scopus
  48. P. Aukrust, T. Ueland, E. Lien et al., “Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy,” American Journal of Cardiology, vol. 83, no. 3, pp. 376–382, 1999. View at Publisher · View at Google Scholar · View at Scopus
  49. R. de Waal Malefyt, J. Abrams, B. Bennett, C. G. Figdor, and J. E. De Vries, “Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes,” The Journal of Experimental Medicine, vol. 174, no. 5, pp. 1209–1220, 1991. View at Publisher · View at Google Scholar · View at Scopus
  50. D. F. Fiorentino, A. Zlotnik, T. R. Mosmann, M. Howard, and A. O'Garra, “IL-10 inhibits cytokine production by activated macrophages,” Journal of Immunology, vol. 147, no. 11, pp. 3815–3822, 1991. View at Google Scholar · View at Scopus
  51. B. Bammens, P. Evenepoel, K. Verbeke, and Y. Vanrenterghem, “Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms,” Kidney International, vol. 64, no. 6, pp. 2238–2243, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. E. Fiaccadori, G. Regolisti, U. Maggiore et al., “Ultrafiltration in heart failure,” The American Heart Journal, vol. 161, no. 3, pp. 439–449, 2011. View at Publisher · View at Google Scholar · View at Scopus